Episode Details

A 43-year-old man starts exercising and ends up in the ER with a CK over 100x the upper limit of normal. His doctor says it’s from training. We don’t think so. In this episode, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through the full case — history, labs, diagnosis, and what actually went wrong — then break down the mechanisms behind the answer, the nocebo research, and what the brand-new 2026 guidelines mean for the 40 million Americans on a drug class you’ve definitely heard of.

We also cover the STOMP trial (do statins actually impair strength gains?), the SAMSON trial (how much of statin intolerance is nocebo?), the difference between myalgia, myositis, and rhabdomyolysis, Austin’s clinical approach to a patient whose strength is declining on a statin, and the treatment escalation pathway for statin-intolerant patients including bempedoic acid, PCSK9 inhibitors, and inclisiran. Plus, where GLP-1 receptor agonists like tirzepatide fit into the cardiovascular risk picture.

Timestamps

• 0:00 — A 43-year-old man is getting weaker, not stronger
• 2:09 — Taking the history: Medications, lifestyle, and red flags
• 12:53 — The labs come back: CK at 18,979
• 16:05 — Metabolic syndrome and the modern treatment approach
• 23:15 — Rhabdomyolysis: What it is and why it’s dangerous
• 29:50 — Final diagnosis and what went wrong with the medications
• 37:15 — 2026 ACC lipid guidelines: What changed
• 40:32 — Three mechanisms: How statins affect muscle
• 47:02 — The nocebo effect and the SAMSON trial
• 54:17 — Do statins impair training? The STOMP trial
• 1:00:30 — Who’s at highest risk for statin muscle problems
• 1:07:36 — What happened to the patient and options if this is you
• 1:14:12 — Five takeaways
• 
  

Five Takeaway

1.  Statin myopathy is real but relatively uncommon. The excess symptom rate above placebo is roughly 1–5% in controlled trials. But in exercising patients, especially on combination therapy, the risk can be higher.
2. There are three proposed mechanisms: reduced energy production from CoQ10 depletion, compromised muscle cell membranes from isoprenoid loss, and accelerated protein breakdown from calcium leak via the ryanodine receptor. Exercise amplifies all three, but the vast majority of people compensate.
3. If you’re on a statin and your strength is going down, talk to your doctor before stopping the medication or changing your training. A CK test can help separate a drug problem from a programming problem
4. The 2026 ACC guidelines list vigorous exercise as a risk factor for statin-associated muscle symptoms for the first time. They also provide statin-intolerant patients a clear escalation pathway: bempedoic acid, ezetimibe, PCSK9 inhibitors, and more.
5. Lower is better for LDL. There’s a 33% relative reduction in cardiovascular events at <55 vs. 70 mg/dL. Lower for longer. Healthy lifestyle changes plus effective lipid-lowering therapy are among the best things you can do for cardiovascular risk.

Next Steps

• For evidence-based resistance training programs: barbellmedicine.com/training-programs
• For individualized training consultation: barbellmedicine.com/coaching
• Explore our full library of articles on health and performance: barbellmedicine.com/resources
• To consult with Drs. Baraki or Feigenbaum email us at support@barbellmedicine.com
• To support us and get ad free listening, plus special product discounts, and exclusive content, go to supercast.barbellmedicine.com

 Resources

Training Plateau Action Plan (free):

https://www.barbellmedicine.com/training-plateau-action-plan/